Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Income: 2014-2025

Historic Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Net Income fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Net Income is -$90.8 million, which was down 38.52% from -$65.5 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Net Income registered a high of -$12.4 million during Q4 2021, and its lowest value of -$90.8 million during Q3 2025.
  • In the last 3 years, Viking Therapeutics' Net Income had a median value of -$25.0 million in 2024 and averaged -$36.2 million.
  • Data for Viking Therapeutics' Net Income shows a maximum YoY tumbled of 262.79% (in 2025) over the last 5 years.
  • Viking Therapeutics' Net Income (Quarterly) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then tumbled by 44.00% to -$35.4 million in 2024, then crashed by 262.79% to -$90.8 million in 2025.
  • Its Net Income was -$90.8 million in Q3 2025, compared to -$65.5 million in Q2 2025 and -$45.6 million in Q1 2025.